Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pacira Pharma (PCRX) Tops Q3 EPS by 7c, Revenues Beat
October 29, 2020 8:07 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.68, $0.07 better than the analyst estimate of $0.61. Revenue for the quarter came in at $117.5 million versus the consensus estimate of $115.15 million.
Third Quarter 2020 Financial Results
Total revenues were $117.5 million in the third quarter of 2020, a 12% increase versus the $104.7 million reported for the third quarter of 2019.EXPAREL net product sales were $113.7 million in the third quarter of 2020, a 12% increase versus the $101.5 million reported for the third quarter of 2019.Third quarter 2020 iovera° net product sales were $2.7 million, a 3% increase versus the $2.6 million reported for the... More